Tag:
Qiagen
Latest Headlines
Latest Headlines
Qiagen snatches up maker of amniotic fluid detection test
Qiagen ($QGEN) snatched up AmniSure International this week as the company continued to beef up its diagnostic offerings through acquisitions. AmniSure, a privately held company based in Boston, is known for marketing a point-of-care diagnostic that determines if a pregnant woman is suffering from a rupture of fetal membranes.
Qiagen's molecular diagnostics buys boost Q1 sales
Qiagen finished its fiscal 2012 first quarter with double-digit growth in both sales and net income, driven by acquisitions and a booming demand for diagnostic test kits.
Qiagen signs diagnostic biomarker deals
Qiagen , a Netherlands-based bioassay company, is developing new cancer biomarker assays after acquiring rights to genes and biomarkers. In agreements with Insight Genetics and Personal Genome
Qiagen to cut up to 10% of workforce
Qiagen ( $QGEN ), a provider of sample and assay technologies, announced this week that it will cut about 8% to 10% of its 3,800 employees as part of an effort to "enhance productivity by...
Qiagen partners with Lilly on companion diagnostic for blood cancer drug
Diagnostics developer Qiagen is continuing its strategy of partnering with large pharmaceutical companies to develop companion diagnostics using its biomarkers. The latest partnership for Qiagen is
Pfizer, Qiagen seize companion diagnostics play
A sign of the business logic behind creating diagnostic tests that complement drugs in development is the manufacturing expansion under way at Qiagen. The biotech's campus is being readied to boost
QIAGEN, Pfizer team up on companion diagnostic
QIAGEN ( $QGEN ) has entered into a partnership with pharma titan Pfizer for the development of a companion molecular diagnostic test for use with an investigational compound in global clinical
QIAGEN completes second U.S. submission of companion diagnostic
QIAGEN ( $QGEN ) has completed its second U.S. submission for the therascreen KRAS RGQ PCR kit as a companion diagnostic for Erbitux (cetuximab), which is used by metastatic colorectal cancer patients.
Qiagen amends offer for Cellestis, provides update on Ipsogen
Qiagen has amended its original proposal to acquire Australia's Cellestis, increasing its per-share offer price to A$3.80 ($4.06) from the original offer price of A$3.55 ($3.79). The amended...
Q&A with QIAGEN about Ipsogen buy
Recently, QIAGEN announced it has entered into talks to purchase a 47 percent initial stake in France's Ipsogen and subsequently make a public offer to fully acquire the company. The potential
